Trollfors B, Bergmark J, Hiesche K, Jagenburg R
Infection. 1984 Jan-Feb;12(1):20-2. doi: 10.1007/BF01641019.
The value of urinary alanine aminopeptidase (AAP) and urinary beta 2-microglobulin as predictors of aminoglycoside-associated nephrotoxicity was studied in 46 patients treated with gentamicin or tobramycin. In three patients serum creatinine increased by more than 50 mumol/l. Urinary AAP increased in virtually all patients. The degree of these increases could not be correlated to subsequent increases in serum creatinine. Increases in urinary beta 2-microglobulin were also seen in many patients who did not show subsequent increases in serum creatinine. Moreover, urinary beta 2-microglobulin was elevated before the onset of aminoglycoside treatment in many patients with septicaemia and malignant diseases, thus making an evaluation of antibiotic-induced changes impossible. These results indicate that neither urinary AAP nor urinary beta 2-microglobulin can be used to predict aminoglycoside-associated nephrotoxicity of clinical importance in individual patients.
在46例接受庆大霉素或妥布霉素治疗的患者中，研究了尿丙氨酸氨基肽酶（AAP）和尿β2-微球蛋白作为氨基糖苷类药物相关肾毒性预测指标的价值。3例患者血清肌酐升高超过50μmol/L。几乎所有患者的尿AAP均升高。这些升高的程度与随后血清肌酐的升高无相关性。许多血清肌酐未随后升高的患者尿β2-微球蛋白也升高。此外，许多败血症和恶性疾病患者在氨基糖苷类药物治疗开始前尿β2-微球蛋白就已升高，因此无法评估抗生素引起的变化。这些结果表明，尿AAP和尿β2-微球蛋白均不能用于预测个别患者具有临床重要性的氨基糖苷类药物相关肾毒性。
